Prostatype Genomics (Sweden) Market Value
| PROGEN Stock | SEK 0.96 0.03 3.03% |
| Symbol | Prostatype |
Prostatype Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prostatype Genomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prostatype Genomics.
| 05/09/2025 |
| 08/07/2025 |
If you would invest 0.00 in Prostatype Genomics on May 9, 2025 and sell it all today you would earn a total of 0.00 from holding Prostatype Genomics AB or generate 0.0% return on investment in Prostatype Genomics over 90 days. Prostatype Genomics is related to or competes with Devyser Diagnostics, IZafe Group, Sprint Bioscience, and Stayble Therapeutics. Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests More
Prostatype Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prostatype Genomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prostatype Genomics AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 77.78 | |||
| Value At Risk | (12.59) | |||
| Potential Upside | 25.0 |
Prostatype Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prostatype Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prostatype Genomics' standard deviation. In reality, there are many statistical measures that can use Prostatype Genomics historical prices to predict the future Prostatype Genomics' volatility.| Risk Adjusted Performance | 0.0069 | |||
| Jensen Alpha | (0.10) | |||
| Total Risk Alpha | (1.65) | |||
| Treynor Ratio | (0.09) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Prostatype Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Prostatype Genomics Backtested Returns
Prostatype Genomics appears to be out of control, given 3 months investment horizon. Prostatype Genomics maintains Sharpe Ratio (i.e., Efficiency) of 0.0561, which implies the firm had a 0.0561 % return per unit of risk over the last 3 months. By analyzing Prostatype Genomics' technical indicators, you can evaluate if the expected return of 0.68% is justified by implied risk. Please evaluate Prostatype Genomics' Coefficient Of Variation of (31,679), variance of 175.12, and Risk Adjusted Performance of 0.0069 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Prostatype Genomics holds a performance score of 4. The company holds a Beta of 0.55, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Prostatype Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Prostatype Genomics is expected to be smaller as well. Please check Prostatype Genomics' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to make a quick decision on whether Prostatype Genomics' historical price patterns will revert.
Auto-correlation | -0.24 |
Weak reverse predictability
Prostatype Genomics AB has weak reverse predictability. Overlapping area represents the amount of predictability between Prostatype Genomics time series from 9th of May 2025 to 23rd of June 2025 and 23rd of June 2025 to 7th of August 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prostatype Genomics price movement. The serial correlation of -0.24 indicates that over 24.0% of current Prostatype Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.24 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Prostatype Genomics lagged returns against current returns
Autocorrelation, which is Prostatype Genomics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Prostatype Genomics' stock expected returns. We can calculate the autocorrelation of Prostatype Genomics returns to help us make a trade decision. For example, suppose you find that Prostatype Genomics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Prostatype Genomics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Prostatype Genomics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Prostatype Genomics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Prostatype Genomics stock over time.
Current vs Lagged Prices |
| Timeline |
Prostatype Genomics Lagged Returns
When evaluating Prostatype Genomics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Prostatype Genomics stock have on its future price. Prostatype Genomics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Prostatype Genomics autocorrelation shows the relationship between Prostatype Genomics stock current value and its past values and can show if there is a momentum factor associated with investing in Prostatype Genomics AB.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Prostatype Stock
Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.